Research on Long-Term Mechanism for Strategic Purchasing of Innovative Drugs Based on Real-World Data

doi:10.19546/j.issn.1674-3830.2026.2.004

China Health Insurance ›› 2026, Vol. 0 ›› Issue (2) : 34-41. DOI: 10.19546/j.issn.1674-3830.2026.2.004

Special Topic Analysis

Research on Long-Term Mechanism for Strategic Purchasing of Innovative Drugs Based on Real-World Data

Author information +

History +

Abstract

The rapid emergence of high-value innovative medicines and the dynamic evolution of their value characteristics pose real challenges to the balance between “basic coverage” and “innovation promotion” within medical insurance funds. This study systematically examines the practical dilemmas faced by medical insurance in terms of decision-making risk, fund affordability, risk sharing, and value identification, and constructs a comprehensive evaluation framework encompassing clinical, economic, social, and innovation value. On this basis, it proposes the establishment of a value-oriented long-term purchasing mechanism supported by real-world data, including value-based risk-sharing agreements, innovative and diversified payment models, and dynamic drug price adjustment mechanisms. The aim is to promote a transformation of medical insurance strategic purchasing from static access decisions to dynamic value management, thereby ensuring fund sustainability while effectively incentivizing pharmaceutical innovation.

Key words

innovative drugs / real-world data / value assessment / strategic purchasing in medical insurance / long-term mechanism

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Research on Long-Term Mechanism for Strategic Purchasing of Innovative Drugs Based on Real-World Data[J]. China Health Insurance. 2026, 0(2): 34-41 https://doi.org/10.19546/j.issn.1674-3830.2026.2.004

References

[1] 毛凯峰,虞杰,王琳宁,等.医保视角下新药创新性认定与价格管理政策的国际对比分析[J].中国药房,2024,35(15):1801-1806.
[2] 常峰,崔鹏磊,张舰云,等.全球视角下药品风险分担协议政策分析[J].卫生经济研究,2016(08): 39-44.
[3] 李伟,郑晓玲,丁锦希,等.创新药物疗效风险分担协议的应用经验及启示[J].中国新药与临床杂志,2021,40(11):750-755.
[4] CHEN Y, DONG H, WEI Y, et al . Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy[J]. BMJ, 2023 (381): e069963.
[5] 官海静,陶立波,韩晟.创新药价格形成与医保准入的影响因素分析[J].中国医疗保险,2024(06): 15-20.
[6] 李芬,刘宇晗,胡嘉浩,等.真实世界数据在创新药医保准入中的应用情境及路径[J].中国医疗保险,2024(11):28-33.
[7] 黄祖彤,周娜,于滨玮,等.真实世界数据应用于评估医保准入药品的综合价值分析[J].中国医疗保险,2025(10):5-18.
[8] 陶立波,宣建伟.经济学评估在医保准入决策中的意义及其应用机制探讨[J].中国医疗保险,2017(07):54-56.
[9] SCHÖTTLER M H, COERTS F B, POSTMA M J, et al. The effect of the drug life cycle price on cost-effectiveness: case studies using real-world pricing data[J]. Value health, 2023, 26(1): 91-98.
[10] HYERACI G, TRIPPOLI S, RIVANO M, et al.Estimation of value-based price for 48 high-technology medical devices[J]. Cureus, 2023, 15(6): e39934.
[11] HOYLE M.Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis[J]. Pharmacoeconomics, 2011, 29(1):1-15.
[12] 胡善联. 中国医保药品价格谈判回顾和展望[J].卫生经济研究,2024,41(01):9-13.
[13] 李俊,方鹏骞,陈王涛,等.经济发展水平、人口老龄化程度和医疗费用上涨对我国医保基金支出的影响分析[J].中国卫生经济,2017,36(01):27-29.
[14] 吕兰婷,张肇龙,王知,等.英国高值创新药支付保障机制研究与启示[J].中国医疗保险, 2023(10):122-128.
[15] 杨姿锐,陶田甜,蒋蓉,等.澳大利亚医保药品价格协议研究及对我国的启示[J].中国卫生经济,2020,39(06):93-96.
[16] BASTIAN A, DUA D, MIRZAHOSSEIN S.The use of risk-sharing agreements to manage costs, mitigate risk, and improve value for pharmaceutical products[J]. Journal of clinical pathways, 2015, 1(3):43-51.
[17] GONÇALVES F R, SANTOS S, SILVA C, et al. Risk-sharing agreements, present and future[J]. Ecancermedicalscience, 2018 (12): 823.
[18] 孙鑫,谭婧,王雯,等.真实世界证据助推药械评价与监管决策[J].中国循证医学杂志,2019, 19(05):521-526.
[19] 孙鑫,谭婧,王雯,等.建立真实世界数据与研究技术规范,促进中国真实世界证据的生产与使用[J].中国循证医学杂志,2019,19(07):755-762.
[20] 谭婧,熊益权,黄诗尧,等.用于药品临床价值和经济价值评价的真实世界数据关键技术考量[J].中国循证医学杂志,2024,24(05):516-522.
[21] HAMPSON G, TOWSE A, DREITLEIN W B, et al.Real-world evidence for coverage decisions: opportunities and challenges[J]. Journal of comparative effectiveness research, 2018, 7(12):1133-1143.